EUCTR2004-000149-39-IT进行中（未招募）不适用
'Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-line Therapy with Fludara plus Alentuzumab (CAMPATH, MabCampth) versus Fludara Alone in patients with B-Cell Chronic Lymphocytic Leukemia'
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Randomized Phase III Trial to evaluate the effect of statins on tumour biology in non-small cell lung cancer. - Neostaton-small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10025050Term: Lung cancer non-small cell stage IMedDRA version: 9.1Level: LLTClassification code 10025051Term: Lung cancer non-small cell stage IIMedDRA version: 9.1Level: LLTClassification code 10025052Term: Lung cancer non-small cell stage IIIMedDRA version: 9.1Level: LLTClassification code 10025053Term: Lung cancer non-small cell stage IIIAEUCTR2007-000903-14-GBImperial College, London184
进行中（未招募）
1 期
A Study to Compare the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Myelofibrosis who were Treated with RuxolitinibPrimary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.MedDRA version: 18.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-005007-13-FRGilead Sciences Inc.150
进行中（未招募）
1 期
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)ocally advanced unresectable/metastatic gastroesophageal adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864EUCTR2020-001990-53-DEMerck Sharp & Dohme LLC878
进行中（未招募）
1 期
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal CarcinomaMetastatic squamous cell carcinoma of the esophagusMedDRA version: 21.0Level: LLTClassification code 10041824Term: Squamous cell carcinoma of esophagusSystem Organ Class: 100000004864EUCTR2020-001911-26-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.862
进行中（未招募）
3 期
Pembrolizumab plus Lenvatinib plus Chemotherapy for the Treatment of Advanced/Metastatic HER2 Negative Gastric/Gastroesophageal Junction AdenocarcinomaJPRN-jRCT2051200127Koh Yasuhiro120